Peripheral Type-2 Diabetes: A Review of PTH-HUMAN as A Potential Drug Target

Target Name: PTRH1

NCBI ID: G138428

PTRH1

Peripheral Type-2 Diabetes: A Review of PTH-HUMAN as A Potential Drug Target

Peripheral Type-2 diabetes (PT2D) is a chronic autoimmune disease that affects millions of people worldwide. The most common cause of PT2D is the insulin resistance, which leads to an increase in the body's resistance to insulin, making it difficult for glucose to enter the cells. Type-2 diabetes is a leading cause of morbidity and mortality, and its prevalence is increasing worldwide.

One of the major challenges in the treatment of PT2D is the development of resistance to the insulin signaling pathway. Insulin resistance is associated with an increased risk of complications such as cardiovascular disease, neuropathy, and lens opacification.

PTH-HUMAN is a potential drug target and biomarker for the treatment of PT2D. PTH stands for Parathyroid hormone, and it is a hormone produced by the parathyroid gland that regulates calcium and phosphorus levels in the body. PTH has been shown to have a beneficial effect on glucose metabolism and has been used in the treatment of hypocalcemia (low calcium levels) in humans.

Research has shown that PTH has a critical role in the regulation of insulin sensitivity and glucose metabolism. It has been shown to improve insulin sensitivity in both muscle and fat tissue, and it has also been shown to increase the sensitivity of peripheral tissues such as the liver and pancreas to insulin.

In addition to its potential therapeutic benefits, PTH has also been shown to be a potential biomarker for the diagnosis and monitoring of PT2D. It has been shown to be elevated in the blood of patients with type-2 diabetes, and it has been used as a diagnostic marker in clinical trials.

The rise in the incidence of type-2 diabetes and the increasing demand for effective treatments has led to the development of new therapies that target the insulin signaling pathway. PTH-HUMAN is one of these therapies, and it has the potential to be a valuable drug target for the treatment of PT2D.

The insulin signaling pathway is a complex network of proteins that regulate glucose metabolism. It is composed of several key components, including the insulin receptor, the insulin-like growth factor 1 (IGF-1), and the phosphatidylinositol (PI) signaling pathway.

The PI signaling pathway is a critical component of the insulin signaling pathway. It is an intracellular signaling pathway that regulates various cellular processes, including cell signaling, protein synthesis, and intracellular transport. The PI signaling pathway is activated by the presence of Pi, which is a phosphate compound.

Insulin is a hormone produced by the pancreas that regulates glucose metabolism. It is an islet hormone that stimulates the release of glucose from the pancreatic beta cells into the bloodstream. Insulin signaling is a critical process that regulates the activity of the insulin receptor, IGF- 1, and other components of the insulin signaling pathway.

The insulin receptor is a transmembrane protein that is located in the cytoplasm of the endothelial cells. It is the protein that Insulin receptor is involved in the signaling process of insulin. When insulin binds to the insulin receptor, it triggers a signaling cascade that regulates various cellular processes, including the upregulation of the PI signaling pathway.

IGF-1 is a protein produced by the liver that is involved in the regulation of glucose metabolism. It is a key component of the PI signaling pathway and is involved in the regulation of cellular processes such as protein synthesis and intracellular transport. IGF-1 plays a critical role in the treatment of hypoglycemia (low blood sugar levels), and it has been shown to have a beneficial effect on glucose metabolism in various cell lines and animal models.

The phosphatidylinositol (PI) signaling pathway is a critical component of the insulin signaling pathway. It is an intracellular signaling pathway that regulates various cellular processes, including

Protein Name: Peptidyl-tRNA Hydrolase 1 Homolog

The "PTRH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTRH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets